Pyrimidine-5-carbonitriles – part III: synthesis and antimicrobial activity of novel 6-(2-substituted propyl)-2,4-disubstituted pyrimidine-5-carbonitriles

Abstract The reaction of 6-(2-methylpropyl or 2-phenylpropyl)-2-thiouracil-5-carbonitriles (4a,b) with various arylmethyl halides, 2-bromoethyl methyl ether, benzyl chloromethyl ether, and 2-bromomethyl-5-nitrofuran in N,N-dimethylformamide or acetone yielded the corresponding substituted thio-3,4-dihydro-4-oxopyrimidine-5-carbonitrile analogues 5a–h, 6a,b, 7, and 8a,b, respectively. Treatment of 5c with phosphorus oxychloride and N,N-dimethylaniline yielded the 4-chloropyrimidine derivative 9, which was allowed to react with various arylthiols, arylamines, and 1-substituted piperazines to yield the respective 4-arylthio 10a–d, 4-arylamino 11a–d, and 4-piperazino 12a,b derivatives. The newly synthesized compounds were tested for in vitro activities against a panel of Gram-positive and Gram-negative bacteria and the yeast-like pathogenic fungus Candida albicans. Compounds 5e, 5f, 5g,h, 7, 8a,b, and 12a display marked antibacterial activity, particularly against the Gram-positive bacteria. None of these compounds are active against C. albicans.

[1]  O. Al-Deeb,et al.  Pyrimidine-5-carbonitriles II: Synthesis and Antimicrobial Activity of Novel 6-Alkyl-2,4-disubstituted pyrimidine-5-carbonitriles , 2013, Drug Research.

[2]  S. M. Abou-Seri,et al.  Synthesis and Bioactivity Evaluation of New 6-Aryl-5-cyano Thiouracils as Potential Antimicrobial and Anticancer Agents , 2012, Molecules.

[3]  O. Al-Deeb,et al.  Synthesis of novel 6-phenyl-2,4-disubstituted pyrimidine-5-carbonitriles as potential antimicrobial agents. , 2011, European journal of medicinal chemistry.

[4]  Liying Ma,et al.  Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2010, Bioorganic & medicinal chemistry.

[5]  R. Loddo,et al.  Synthesis of Novel Uracil Non‐Nucleoside Derivatives as Potential Reverse Transcriptase Inhibitors of HIV‐1 , 2009, Archiv der Pharmazie.

[6]  C. Sincak,et al.  Iclaprim, a Novel Diaminopyrimidine for the Treatment of Resistant Gram-Positive Infections , 2009, The Annals of pharmacotherapy.

[7]  D. R. Patil,et al.  A novel and efficient one step synthesis of 2-amino-5-cyano-6-hydroxy-4-aryl pyrimidines and their anti-bacterial activity. , 2009, European journal of medicinal chemistry.

[8]  L. Altucci,et al.  Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities. , 2008, Bioorganic & medicinal chemistry letters.

[9]  Ying Guo,et al.  The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors. , 2007, Bioorganic & medicinal chemistry.

[10]  M. Al-Omar,et al.  Synthesis of Novel Uracil Non-Nucleosides Analogues of 3,4-Dihydro-2-Alkylthio-6-benzyl-4-oxopyrimidines and 6-benzyl-1-ethoxymethyl-5-isopropyluracil , 2007 .

[11]  F. Zoulim,et al.  In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants , 2007, Antimicrobial Agents and Chemotherapy.

[12]  A. Mai,et al.  Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. , 2007, Bioorganic & medicinal chemistry letters.

[13]  S. Kasibhatla,et al.  Discovery of substituted 4-anilino-2-(2-pyridyl)pyrimidines as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. Part 1: structure-activity relationships of the 4-anilino group. , 2006, Bioorganic & medicinal chemistry.

[14]  Frank Goebel,et al.  Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects , 2006, AIDS.

[15]  G. Maga,et al.  Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[16]  D. Tyrrell,et al.  Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication. , 2006, Journal of medicinal chemistry.

[17]  J. Wu,et al.  Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase. , 2006, Bioorganic chemistry.

[18]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[19]  R. Schinazi,et al.  5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens , 2005, Cancer Chemotherapy and Pharmacology.

[20]  Jan Balzarini,et al.  In Vitro Evaluation of Nonnucleoside Reverse Transcriptase Inhibitors UC-781 and TMC120-R147681 as Human Immunodeficiency Virus Microbicides , 2004, Antimicrobial Agents and Chemotherapy.

[21]  M. Massoud,et al.  Synthesis of Certain 6-(Arylthio)uracils and Related Derivatives as Potential Antiviral Agents , 2004 .

[22]  P. Shukla,et al.  Chloropyrimidines as a new class of antimicrobial agents. , 2002, Bioorganic & medicinal chemistry.

[23]  K. Hotchkiss,et al.  Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase. , 2001, Biochemical pharmacology.

[24]  P. Shukla,et al.  Suitably functionalised pyrimidines as potential antimycotic agents. , 2000, Bioorganic & medicinal chemistry letters.

[25]  K. Ghoshal,et al.  An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. , 1997, Biochemical pharmacology.

[26]  P. Hartman,et al.  Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone , 1996, Antimicrobial agents and chemotherapy.

[27]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[28]  A. Mai,et al.  3,4-Dihydro-2-Alkoxy-6-Benzyl-4-Oxopyrimidines (DABOs): A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1 , 1993 .

[29]  S. Amyes.  Comparative antibacterial spectrum of trimethoprim and brodimoprim. , 1993, Journal of chemotherapy.

[30]  J. Hamilton-miller,et al.  Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. , 1993, Journal of chemotherapy.

[31]  D. R. McCalla,et al.  Mode of Action of Nitrofurazone , 1970, Journal of bacteriology.

[32]  H. Kohlhage,et al.  In vitro and in vivo virostatic properties of alkylated pyrimidines against DNA and RNA viruses. , 1969, Chemotherapy.

[33]  M. Madoff,et al.  Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. , 1968, JAMA.

[34]  M. Finland,et al.  Nitrofurantoin; clinical and laboratory studies in urinary tract infections. , 1955, A.M.A. archives of internal medicine.